Amgen, Canadian Solar, and Diana Shipping are three undervalued stocks with high potential for growth that can enhance portfolio returns.
These high-growth biotech stocks are certainly worth considering for investors looking for market-beating returns in the long-term.
Our economy is on the up and up, and investing is a must,. Let's review the most undervalued S&P 500 stocks to buy in April.
By Ian Cooper , InvestorPlace Contributor
Mar 27, 2024
Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three.
Warren Buffett stocks and Berkshire Hathaway's portfolio of companies are hidden investment vehicles hiding in plain sight.
Biotech stocks can offer some of the best risk vs. reward payoff in the stock market. These three are ones to buy now.
While investing in Dow stocks – that is, the 30 companies making up the Dow Jones Industrial Average – might seem incredibly boring, investors shouldn’t…
The catalyst for top weight-loss stocks comes down to one sweeping attribute: a burgeoning total addressable market. According to a Goldman Sachs analysis, earlier last…
Explore pharma stocks to sell in February: Eli Lilly, Amgen, BioNTech face overvaluation, volatility, urging investor action.
Last October, life sciences giant Thermo Fisher Scientific (NYSE:TMO) inadvertently laid out the case for contrarian biotech stocks. According to Reuters, the company revealed that…
Obesity drug sales boomed in 2023 and will continue in 2024 making these weight loss stocks attratcive considerations for pharma investors.
The venerable index is more representative of today's economy and these three Dow stocks to buy are brightly shining component stars.
The best weight-loss drug stocks are improving the drugs or developing new, potentially superior, weight-loss treatments.
Buying Dogs of the Dow stocks is an attractive strategy that involves buying stocks with high dividend yields that have often underperformed.
Xeris Biopharma stock is rising higher on Wednesday as investors in XERS shares react to a new exclusive worldwide license agreement.
It's now time to take a look at these three biotech stocks to buy, as each one is currently within TradeSmith's "Green Zone."
Investors appear to be viewing Amgen's recent job cuts as a positive today, with buying pressure resulting in a 1% move higher in AMGN stock.
The demand for obesity drugs is intense and is likely to only greatly increase going forward, since over 40% of Americans were obese in 2020.
While these undervalued biotech stocks have struggled of late, they could surprise investors and prove to be long-term winners.
These biotech stocks to buy represent tremendous bets and are essentially fueling innovation and portfolio growth at the same time.